Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China

Roche has pledged nearly $300 million (2.04 billion Chinese yuan, approximately $282–$283 million) to build a new biopharma manufacturing facility in Shanghai, China1234.

The new plant will focus on the domestic production of Vabysmo (faricimab-svoa), a bispecific antibody used to treat several retinal diseases including age-related macular degeneration and diabetic macular edema123.

The facility will be located in Zhangjiang Hi-Tech Park, Pudong New Area, and will occupy about 25,000 to 35,300 square meters23.

Construction is expected to be completed in 2029, with operations commencing in 2031123.

This project is part of Roche’s strategy to localize its pharmaceutical value chain and meet the increasing demand for innovative medicines in China123.

Roche will prioritize sustainable practices at the new site, including using 100% green electricity for its operations3.

The new hub marks Roche’s second manufacturing plant for branded medicines in China and underscores the company's commitment to the Chinese market3.

Sources:

1. https://www.thepharmaletter.com/biotechnology/roche-shanghai-new-eye-drug-plant

2. https://www.worldpharmaceuticals.net/news/roche-to-build-new-manufacturing-facility-in-china/

3. https://www.fiercepharma.com/pharma/roche-pledges-nearly-300m-establish-new-vabysmo-production-plant-china

4. https://healtheconomics.com/roche-invests-300m-in-new-vabysmo-production-plant-in-china/